SNY · Sanofi
Price & Indicators
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SNY
this stock
Sanofi
|
$102.14B | -11.7% | — | — | 0.3% |
|
LLY
ELI LILLY & Co
|
$1.06T | +3.8% | +44.7% | 37.7 | 0.8% |
|
JNJ
Johnson & Johnson
|
$641.88B | +28.3% | +6.0% | 30.9 | 0.9% |
|
ABBV
AbbVie Inc.
|
$455.77B | +12.5% | +8.6% | 72.9 | 1.1% |
|
MRK
Merck & Co., Inc.
|
$357.02B | +36.7% | +1.3% | 115.8 | 1.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SNY | -3.5% | -2.3% | -4.1% | -3.6% | -11.7% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -2.4% | -0.6% | -21.9% | -3.2% | -23.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.